Fibroblast Growth Factor 11 Promotes Immune Escape of Cervical Cancer Cells by Promoting Infiltration of CD4 ⁺ T Cells, Particularly Regulatory T Cells

<b><i>Background:</i></b> Cervical cancer (CC) is one of the leading gynecological malignancies. Immunotherapy has shown limited efficacy, particularly for advanced, recurrent CC. Consequently, dependable prognostic biomarkers and treatment targets are needed. <b><i>Methods and Results:</i></b> In this study, we aimed to determine the association of fibroblast growth factor 11 (<i>FGF11</i>) with prognosis. <i>FGF11</i> expression was assessed in both tissues and cells through immunohistochemical and immunocytochemical staining. Immune cell infiltration was predicted using Tumor Immune Estimation Resource (TIMER) and TIMER2.0. <i>FGF11</i> was significantly correlated with prognosis. <i>FGF11</i> expression was significantly elevated in CC tissues. Moreover, <i>FGF11</i> expression was significantly higher in SiHa and HeLa cancer cells than in normal H8 cells, particularly SiHa cells. Enrichment analyses suggested that <i>FGF11</i> may be involved in arachidonic acid and linoleic acid metabolism, indicating roles in epithelial adhesion and cell differentiation. <i>FGF11</i> correlated positively with CD4⁺ T, regulatory T, and dendritic cells but negatively with CD8⁺ T cells. <i>FGF11</i> also correlated positively with Cluster of Differentiation 4 (<i>CD4), CD25,</i> Forkhead box P3 <i>(FOXP3),</i> and transforming growth factor β but negatively with human leukocyte antigens. <b><i>Conclusions:</i></b> <i>FGF11</i> may enhance the immune escape abilities of CC cells by promoting CD4⁺ T cell infiltration (particularly regulatory T cells) into the tumor microenvironment, leading to poor prognosis. These findings provide a reference for the exploration of <i>FGF11</i> as a prognostic biomarker and treatment target in CC.